GSTM1 and colorectal carcinoma: This randomized controlled trial will determine if it is safe to delay surveillance colonoscopy procedures by 1 to 2 years in patients with an elevated risk for CRC who have low FIT Hb levels and are undergoing surveillance colonoscopy with a 3- or 5-year surveillance interval.